43

Background: Polycystic ovary syndrome (PCOS) is among the most prevalent endocrine disorders in women of reproductive age, with a global prevalence ranging from 8% to 13%, depending on diagnostic criteria. It is a multifactorial condition associated with hormonal imbalance, insulin resistance, chronic inflammation, and genetic predisposition.Objective: To summarize current evidence on the pathogenesis, diagnostic approaches, and treatment strategies for PCOS, with an emphasis on personalized medicine and emerging therapeutic directions.Methods: A systematic literature review was conducted in accordance with PRISMA guidelines. Sources included PubMed, Google Scholar, and eLibrary. Inclusion criteria encompassed peer-reviewed studies focused on reproductive endocrinology in women aged 18 to 45 years, using established diagnostic criteria (NIH, Rotterdam, AE-PCOS). Studies of low methodological quality, small sample size, or without full-text availability were excluded. Fifty high-quality publications were selected for final analysis.Results: PCOS is recognized as a systemic disorder necessitating a multidisciplinary and individualized treatment approach. Conventional management includes pharmacological therapies such as combined oral contraceptives, insulin sensitizers, and ovulation induction agents. Lifestyle modifications and assisted reproductive technologies (ART) significantly enhance reproductive outcomes. Emerging evidence suggests a critical role for genetic variants, gut microbiota alterations, and novel biomarkers in advancing diagnostic accuracy and tailoring treatment.

  • Ўқишлар сони 43
  • Нашр санаси 10-06-2025
  • Мақола тилиIngliz
  • Саҳифалар сони 148-161
English

Background: Polycystic ovary syndrome (PCOS) is among the most prevalent endocrine disorders in women of reproductive age, with a global prevalence ranging from 8% to 13%, depending on diagnostic criteria. It is a multifactorial condition associated with hormonal imbalance, insulin resistance, chronic inflammation, and genetic predisposition.Objective: To summarize current evidence on the pathogenesis, diagnostic approaches, and treatment strategies for PCOS, with an emphasis on personalized medicine and emerging therapeutic directions.Methods: A systematic literature review was conducted in accordance with PRISMA guidelines. Sources included PubMed, Google Scholar, and eLibrary. Inclusion criteria encompassed peer-reviewed studies focused on reproductive endocrinology in women aged 18 to 45 years, using established diagnostic criteria (NIH, Rotterdam, AE-PCOS). Studies of low methodological quality, small sample size, or without full-text availability were excluded. Fifty high-quality publications were selected for final analysis.Results: PCOS is recognized as a systemic disorder necessitating a multidisciplinary and individualized treatment approach. Conventional management includes pharmacological therapies such as combined oral contraceptives, insulin sensitizers, and ovulation induction agents. Lifestyle modifications and assisted reproductive technologies (ART) significantly enhance reproductive outcomes. Emerging evidence suggests a critical role for genetic variants, gut microbiota alterations, and novel biomarkers in advancing diagnostic accuracy and tailoring treatment.

№ Муаллифнинг исми Лавозими Ташкилот номи
1 Shukurov F.I. ! Tashkent State Medical University
№ Ҳавола номи
1 [1] Adamyan LV, Andreeva EN, Absatarova YS, et al. [Clinical guidelines «Polycystic Ovary Syndrome»]. Probl Endokrinol (Mosk). 2022;68(2):112–127. Russian. doi:10.14341/probl12874[2] Artymuk NV, Tachkova OA. New Insights into the Pathogenesis and Treatment of Polycystic Ovary Syndrome. RMJ. Mother and Child. 2021;4(1):17–22. doi:10.32364/2618-8430-2021-4-1-17-22[3] Efimenko VV, et al. New Aspects in the Diagnosis and Treatment of Polycystic Ovary Syndrome. Medical Council. 2024;(6):140–147.[4] Zaidieva YZ, Kazantseva VD. Polycystic Ovary Syndrome in Middle-Aged Women: Associated Diseases. Russian Bulletin of Obstetrics and Gynecology. 2022;22(1):45–51.[5] Bolkina YuS, Radynova SB, Khramov AA. Management Strategies for Patients with Polycystic Ovary Syndrome and Insulin Resistance. Science Journal. 2021;(7).[6] Gasieva DM, Sheremetyeva EV, Kalashnikova MF, Dzgoeva FKh, Alborova ET. Polycystic Ovary Syndrome: New and Promising Treatment Options. Problems of Endocrinology. 2024;70(4):103–113. doi:10.14341/probl13400[7] Danielyan RM, Gzgzyan AM. Infertility Treatment in Women with Polycystic Ovary Syndrome Using Assisted Reproductive Technologies. Journal of Obstetrics and Gynecological Diseases. 2017;66(5):37–45.[8] Panarina OV, Rashidova MA, Belenkaya LV, et al. Current Understanding of the Pathogenesis of Polycystic Ovary Syndrome: A Literature Review. Acta Biomedica Scientifica. 2017;2(4):9–14. doi:10.12737/article_59fad50f053c20.99807656[9] Pshenichnikova TB, Pshenichnikova EB. Optimization of the Management of Women with Polycystic Ovary Syndrome, Metabolic Syndrome, and Thrombophilia. RMJ. 2006;49–52.[10] Suchek KA, Frolova AS, Petrov YuA. Diagnosis and Treatment of Endocrine Infertility Associated with Polycystic Ovary Syndrome. International Journal of Applied and Fundamental Research. 2020;(1):42–46.[11] Sosnova EA, Gracheva TS, Demura TA, Krot MA. Morphological Features of Polycystic Ovary Syndrome and Diagnostic Errors. Archives of Obstetrics and Gynecology named after V.F. Snegirev. 2022;9(3):143–151. doi:10.17816/2313-8726-2022-9-3-143-151[12] Sosnova AE, GrachevaTS. Outcomes of Surgical Treatment for Polycystic Ovary Syndrome in Women of Reproductive Age. Archives of Obstetrics and Gynecology named after V.F. Snegirev. 2023;10(2):105–111. doi:10.17816/2313-8726-2023-10-2-105-111[13] Safi AT, Orazov MR, Kalinchenko SYu. Vitamin D Deficiency and Polycystic Ovary Syndrome: Versions and Controversies. Questions of Dietetics. 2018;8(3):33–41.[14] Myagchenkova KI, Khashchenko EP, Uvarova EV. Metabolic Disorders and Insulin Resistance in the Pathogenesis of Polycystic Ovary Syndrome and the Mechanisms of Metformin Action. Reproductive Health of Children and Adolescents. 2020;16(2):40–52.[15] Zakharov IS, Bukreeva EL. Oxidative Stress in Polycystic Ovary Syndrome: Prognostic Significance and Correction Strategies. Gynecology. 2018;20(1):35–38.[16] Rakhmetova MR, et al. Features of Diagnosis and Treatment of Endocrine Infertility. Academic Research in Educational Sciences. 2022;3(4):722–728.[17] Beglova AYu, ElginaSI. Metabolic and Cardiovascular Risks in Women of Reproductive Age with Polycystic Ovary Syndrome. Mother and Child in Kuzbass. 2018;(4):44–49.[18] Zaitseva OA, et al. Rehabilitation of Patients After Surgical Treatment of Polycystic Ovary Syndrome. Rehabilitology. 2024;2(1):133–148.[19] Ganie MA, Vasudevan V, Wani IA, et al. Epidemiology, pathogenesis, genetics & management of polycystic ovary syndrome in India. Indian J Med Res. 2019;150(4):333–344. doi:10.4103/ijmr.IJMR_1937_17[20] Papaetis GS, Kyriacou A. GLP-1 receptor agonists, polycystic ovary syndrome and reproductive dysfunction: Current research and future horizons. Adv Clin Exp Med. 2022;31(11):1265–1274. doi:10.17219/acem/151695[21] Heshmati J, Moini A, Sepidarkish M, et al. Effects of curcumin supplementation on blood glucose, insulin resistance and androgens in patients with polycystic ovary syndrome: A randomized double-blind placebo-controlled clinical trial. Phytomedicine. 2021;80:153395. doi:10.1016/j.phymed.2020.153395[22] Vitek W, Hoeger K, Legro RS. Treatment strategies for infertile women with polycystic ovary syndrome. Minerva Ginecol. 2016;68(4):450–457.[23] Garg D, Tal R. The role of AMH in the pathophysiology of polycystic ovarian syndrome. Reprod Biomed Online. 2016;33(1):15–28. doi:10.1016/j.rbmo.2016.04.007[24] Abdalla M, Deshmukh H, Atkin SL, Sathyapalan T. miRNAs as a novel clinical biomarker and therapeutic targets in polycystic ovary syndrome (PCOS): A review. Life Sci. 2020;259:118174. doi:10.1016/j.lfs.2020.118174[25] Teede HJ, Tay CT, Laven JJE, et al. International PCOS Network. Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Eur J Endocrinol. 2023;189(2):G43–G64. doi:10.1093/ejendo/lvad096[26] Szczuko M, Kikut J, Szczuko U, et al. Nutrition Strategy and Life Style in Polycystic Ovary Syndrome-Narrative Review. Nutrients. 2021;13(7):2452. doi:10.3390/nu13072452[27] Kazemi M, Kim JY, Wan C, Xiong JD, et al. Comparison of dietary andphysical activity behaviors in women with and without polycystic ovary syndrome: a systematic review and meta-analysis of 39471 women. Hum Reprod Update. 2022;28(6):910–955. doi:10.1093/humupd/dmac023[28] Nazirudeen R, Sridhar S, Priyanka R, et al. A randomized controlled trial comparing myoinositol with metformin versus metformin monotherapy in polycystic ovary syndrome. Clin Endocrinol (Oxf). 2023;99(2):198–205. doi:10.1111/cen.14931[29] Dietz de Loos A, Jiskoot G, Beerthuizen A, et al. Metabolic health during a randomized controlled lifestyle intervention in women with PCOS. Eur J Endocrinol. 2021;186(1):53–64. doi:10.1530/EJE-21-0669[30] Munro MG, Balen AH, Cho S, et al. FIGO Committee on Menstrual Disorders and Related Health Impacts, and FIGO Committee on Reproductive Medicine, Endocrinology, and Infertility. The FIGO Ovulatory Disorders Classification System. Fertil Steril. 2022;118(4):768–786. doi:10.1016/j.fertnstert.2022.07.009[31] He Y, Lu Y, Zhu Q, et al. Influence of metabolic syndrome on female fertility and in vitro fertilization outcomes in PCOS women. Am J Obstet Gynecol. 2019;221(2):138.e1–138.e12. doi:10.1016/j.ajog.2019.03.011[32] Komorowski AS, Hughes L, Sarkar P, et al. Antimüllerian hormone level predicts ovulation in women with polycystic ovary syndrome treated with clomiphene and metformin. Fertil Steril. 2024;121(4):660–668. doi:10.1016/j.fertnstert.2023.12.031[33] Jamilian M, Mansury S, Bahmani F, et al. The effects of probiotic and selenium co-supplementation on parameters of mental health, hormonal profiles, and biomarkers of inflammation and oxidative stress in women with polycystic ovary syndrome. J Ovarian Res. 2018;11(1):80. doi:10.1186/s13048-018-0457-1[34] Heshmati J, Moini A, Sepidarkish M, et al. Effects of curcumin supplementation on blood glucose, insulin resistance and androgens in patients with polycystic ovary syndrome: A randomized double-blind placebo-controlled clinical trial. Phytomedicine. 2021;80:153395. doi:10.1016/j.phymed.2020.153395[35] Samarasinghe SNS, Leca B, Alabdulkader S, et al. Bariatric surgery for spontaneous ovulation in women living with polycystic ovary syndrome: the BAMBINI multicentre, open-label, randomised controlled trial. Lancet. 2024;403(10443):2489–2503. doi:10.1016/S0140-6736(24)00538-5[36] Jiskoot G, Dietz de Loos A, Beerthuizen A, et al. Long-term effects of a three-component lifestyle intervention on emotional well-being in women with Polycystic Ovary Syndrome (PCOS): A secondary analysis of a randomized controlled trial. PLoS One. 2020;15(6):e0233876. doi:10.1371/journal.pone.0233876[37] Hu M, Zhang Y, Li X, et al. TLR4-Associated IRF-7 and NFκB Signaling Act as a Molecular Link Between Androgen and Metformin Activities and Cytokine Synthesis in the PCOS Endometrium. J Clin Endocrinol Metab. 2021;106(4):1022–1040. doi:10.1210/clinem/dgaa951[38] Pastoor H, Mousa A, Bolt H, et al. Sexual function in women with polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update. 2024;30(3):323–340. doi:10.1093/humupd/dmad034[39] Zhang J, Zhou K, Luo X, et al. Variation of Laparoscopic Ovarian Drilling for Clomiphene Citrate-resistant Patients with Polycystic Ovary Syndrome and Infertility: A Meta-analysis. J Minim Invasive Gynecol. 2020;27(5):1048–1058. doi:10.1016/j.jmig.2019.06.022[40] Salamun V, Jensterle M, JanezA, et al. Liraglutide increases IVF pregnancy rates in obese PCOS women with poor response to first-line reproductive treatments: a pilot randomized study. Eur J Endocrinol. 2018;179(1):1–11. doi:10.1530/EJE-18-0175[41] Zad Z, Jiang VS, Wolf AT, et al. Predicting polycystic ovary syndrome with machine learning algorithms from electronic health records. Front Endocrinol (Lausanne). 2024;15:1298628. doi:10.3389/fendo.2024.1298628[42] Magzoub R, Kheirelseid EAH, Perks C, et al. Does metformin improve reproduction outcomes for non-obese, infertile women with polycystic ovary syndrome? Meta-analysis and systematic review. Eur J Obstet Gynecol Reprod Biol. 2022;271:38–62. doi:10.1016/j.ejogrb.2022.01.025[43] van der Ham K, Moolhuijsen LME, Brewer K, et al. Clustering Identifies Subtypes With Different Phenotypic Characteristics in Women With Polycystic Ovary Syndrome. J Clin Endocrinol Metab. 2024;109(12):3096–3107. doi:10.1210/clinem/dgae298[44] Shan Y, Han X, Yang C, et al. The impact of metabolic surgery onnatural conception rates in women with infertility, obesity and polycystic ovary syndrome: a retrospective study. Surg Obes Relat Dis. 2024;20(3):237–243. doi:10.1016/j.soard.2023.09.024[45] Moini A, Rezaee T, Aleyasin A, et al. The effect of metabolic syndrome on controlled ovarian stimulation outcome in infertile women with polycystic ovary syndrome undergoing assisted reproductive technology cycles. Arch Endocrinol Metab. 2023;67(1):111–118. doi:10.20945/2359-3997000000518[46] Talebi S, Shab-Bidar S, Moini A, et al. The effects of time-restricted eating alone or in combination with probiotic supplementation in comparison with a calorie-restricted diet on endocrine and metabolic profiles in women with polycystic ovary syndrome: A randomized clinical trial. Diabetes Obes Metab. 2024;26(10):4468–4479. doi:10.1111/dom.15801[47] Malekzadeh F, Mohammadi M, Navid B, et al. Awareness of Polycystic Ovary Syndrome among Schoolgirls and Their Mothers: A Cross-Sectional Study. Int J Fertil Steril. 2023;17(4):299–305. doi:10.22074/ijfs.2023.543119.1224[48] Nandi ER, Fatima P, Deeba F, et al. Association between Serum Vitamin D and Metabolic Syndrome in Women with Polycystic Ovary Syndrome. Mymensingh Med J. 2023;32(1):125–134.[49] Alvero R. Reproductive endocrinology and infertility in 2024: promise and turmoil. Curr Opin Obstet Gynecol. 2024;36(4):209–210. doi:10.1097/GCO.0000000000000964[50] Cedars MI. Reproductive endocrinology and infertility in the year 2035. Fertil Steril. 2024;122(2):228–229. doi:10.1016/j.fertnstert.2024.03.004
Кутилмоқда